;PMID: 3021941
;source_file_859.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..157] = [t:46..157]
;2)section:[e:161..219] = [t:161..219]
;3)sentence:[e:223..540] = [t:223..540]
;4)sentence:[e:541..825] = [t:541..825]
;5)sentence:[e:826..919] = [t:826..919]
;6)sentence:[e:920..1064] = [t:920..1064]
;7)sentence:[e:1065..1237] = [t:1065..1237]
;8)section:[e:1241..1271] = [t:1241..1271]
;9)section:[e:1275..1319] = [t:1275..1319]

;section 0 Span:0..40
;J Hypertens Suppl. 1986 Oct;4(4):S33-42.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Hypertens) (NNP:[12..17] Suppl)
        (.:[17..18] .) (CD:[19..23] 1986) (DT:[24..30] Oct;4-LRB-)
        (CD:[30..32] 4-RRB-) (CD:[32..36] :S33) (::[36..37] -) (CD:[37..39] 42)
        (.:[39..40] .)))

;sentence 1 Span:46..157
;Cytochrome P450-dependent arachidonate metabolism in renomedullary cells: 
;formation of Na+K+-ATPase inhibitor.
;[46..61]:cyp450:"Cytochrome P450"
;[72..84]:substance:"arachidonate"
;[134..146]:substance:"Na+K+-ATPase"
;[147..156]:substance:"inhibitor"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP
          (NML (NN:[46..56] Cytochrome) (NN:[57..61] P450))
          (HYPH:[61..62] -) (JJ:[62..71] dependent))
        (NN:[72..84] arachidonate) (NN:[85..95] metabolism))
      (PP-LOC (IN:[96..98] in)
        (NP (JJ:[99..112] renomedullary) (NNS:[113..118] cells))))
    (::[118..119] :)
    (NP
      (NP (NN:[121..130] formation))
      (PP (IN:[131..133] of)
        (NP (NN:[134..146] Na+K+-ATPase) (NN:[147..156] inhibitor))))
    (.:[156..157] .)))

;section 2 Span:161..219
;Carroll MA, Schwartzman M, Abraham NG, Pinto A, McGiff JC.
(SEC
  (FRAG (NNP:[161..168] Carroll) (NNP:[169..171] MA) (,:[171..172] ,)
        (NNP:[173..184] Schwartzman) (NNP:[185..187] M,)
        (NNP:[188..195] Abraham) (NNP:[196..198] NG) (,:[198..199] ,)
        (NNP:[200..205] Pinto) (NNP:[206..207] A) (,:[207..208] ,)
        (NNP:[209..215] McGiff) (NNP:[216..219] JC.)))

;sentence 3 Span:223..540
;The medullary portion of the thick ascending limb of the loop of Henle
;(mTALH)  has one of the highest concentrations of Na+K+-ATPase found in
;mammalian  tissues, reflecting the importance of this nephron segment in the
;regulation of  extracellular fluid volume, as active sodium transport is
;driven by  Na+K+-ATPase.
;[344..356]:substance:"Na+K+-ATPase"
;[472..477]:substance:"fluid"
;[496..502]:substance:"sodium"
;[527..539]:substance:"Na+K+-ATPase"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[223..226] The) (JJ:[227..236] medullary)
            (NN:[237..244] portion))
        (PP (IN:[245..247] of)
          (NP
            (NP (DT:[248..251] the) (JJ:[252..257] thick)
                (JJ:[258..267] ascending) (NN:[268..272] limb))
            (PP (IN:[273..275] of)
              (NP
                (NP (DT:[276..279] the) (NN:[280..284] loop))
                (PP (IN:[285..287] of)
                  (NP (NNP:[288..293] Henle))))))))
      (NP (-LRB-:[294..295] -LRB-) (NN:[295..300] mTALH)
          (-RRB-:[300..301] -RRB-)))
    (VP (VBZ:[303..306] has)
      (NP
        (NP
          (NP (CD:[307..310] one))
          (PP (IN:[311..313] of)
            (NP
              (NP (DT:[314..317] the) (JJS:[318..325] highest)
                  (NN:[326..340] concentrations))
              (PP (IN:[341..343] of)
                (NP (NN:[344..356] Na+K+-ATPase))))))
        (VP (VBN:[357..362] found)
          (NP (-NONE-:[362..362] *))
          (PP-LOC (IN:[363..365] in)
            (NP (JJ:[366..375] mammalian) (NNS:[377..384] tissues)))))
      (,:[384..385] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[385..385] *))
        (VP (VBG:[386..396] reflecting)
          (NP
            (NP (DT:[397..400] the) (NN:[401..411] importance))
            (PP (IN:[412..414] of)
              (NP (DT:[415..419] this) (NN:[420..427] nephron)
                  (NN:[428..435] segment))))
          (PP (IN:[436..438] in)
            (NP
              (NP (DT:[439..442] the) (NN:[443..453] regulation))
              (PP (IN:[454..456] of)
                (NP (JJ:[458..471] extracellular) (NN:[472..477] fluid)
                    (NN:[478..484] volume)))))
          (,:[484..485] ,)
          (SBAR-ADV (IN:[486..488] as)
            (S
              (NP-SBJ-1 (JJ:[489..495] active) (NN:[496..502] sodium)
                        (NN:[503..512] transport))
              (VP (VBZ:[513..515] is)
                (VP (VBN:[516..522] driven)
                  (NP-1 (-NONE-:[522..522] *))
                  (PP (IN:[523..525] by)
                    (NP-LGS (NN:[527..539] Na+K+-ATPase))))))))))
    (.:[539..540] .)))

;sentence 4 Span:541..825
;We have isolated cells derived primarily from the mTALH of the  outer medulla
;of rabbit kidney and have identified a cytochrome P450-dependent 
;mono-oxygenase system which metabolizes arachidonic acid to two biologically 
;active oxygenated peaks, each containing two or more products.
;[658..673]:cyp450:"cytochrome P450"
;[685..699]:substance:"mono-oxygenase"
;[725..741]:substance:"arachidonic acid"
;[816..824]:substance:"products"
(SENT
  (S
    (NP-SBJ (PRP:[541..543] We))
    (VP
      (VP (VBP:[544..548] have)
        (VP (VBN:[549..557] isolated)
          (NP
            (NP (NNS:[558..563] cells))
            (VP (VBN:[564..571] derived)
              (NP (-NONE-:[571..571] *))
              (ADVP (RB:[572..581] primarily))
              (PP (IN:[582..586] from)
                (NP
                  (NP (DT:[587..590] the) (NN:[591..596] mTALH))
                  (PP (IN:[597..599] of)
                    (NP
                      (NP (DT:[600..603] the) (JJ:[605..610] outer)
                          (NN:[611..618] medulla))
                      (PP (IN:[619..621] of)
                        (NP (NN:[622..628] rabbit) (NN:[629..635] kidney)))))))))))
      (CC:[636..639] and)
      (VP (VBP:[640..644] have)
        (VP (VBN:[645..655] identified)
          (NP
            (NP (DT:[656..657] a)
              (ADJP
                (NML (NN:[658..668] cytochrome) (NN:[669..673] P450))
                (HYPH:[673..674] -) (JJ:[674..683] dependent))
              (NN:[685..699] mono-oxygenase) (NN:[700..706] system))
            (SBAR
              (WHNP-1 (WDT:[707..712] which))
              (S
                (NP-SBJ-1 (-NONE-:[712..712] *T*))
                (VP (VBZ:[713..724] metabolizes)
                  (NP (JJ:[725..736] arachidonic) (NN:[737..741] acid))
                  (PP (TO:[742..744] to)
                    (NP
                      (NP (CD:[745..748] two)
                        (ADJP (RB:[749..761] biologically)
                              (JJ:[763..769] active))
                        (JJ:[770..780] oxygenated) (NNS:[781..786] peaks))
                      (,:[786..787] ,)
                      (NP
                        (NP (DT:[788..792] each))
                        (VP (VBG:[793..803] containing)
                          (NP
                            (QP (CD:[804..807] two) (CC:[808..810] or)
                                (JJR:[811..815] more))
                            (NNS:[816..824] products)))))))))))))
    (.:[824..825] .)))

;sentence 5 Span:826..919
;One of the peaks  potently inhibits cardiac Na+K+-ATPase and the other
;relaxes blood vessels.
;[870..882]:substance:"Na+K+-ATPase"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (CD:[826..829] One))
        (PP (IN:[830..832] of)
          (NP (DT:[833..836] the) (NNS:[837..842] peaks))))
      (ADVP (RB:[844..852] potently))
      (VP (VBZ:[853..861] inhibits)
        (NP (JJ:[862..869] cardiac) (NN:[870..882] Na+K+-ATPase))))
    (CC:[883..886] and)
    (S
      (NP-SBJ (DT:[887..890] the) (JJ:[891..896] other))
      (VP (VBZ:[897..904] relaxes)
        (NP (NN:[905..910] blood) (NNS:[911..918] vessels))))
    (.:[918..919] .)))

;sentence 6 Span:920..1064
;We  report that formation of these oxygenated arachidonate metabolites is
;stimulated  by arginine vasopressin (AVP) and salmon calcitonin (SCT).
;[966..990]:substance:"arachidonate metabolites"
;[1009..1029]:substance:"arginine vasopressin"
;[1031..1034]:substance:"AVP"
;[1040..1057]:substance:"salmon calcitonin"
;[1059..1062]:substance:"SCT"
(SENT
  (S
    (NP-SBJ (PRP:[920..922] We))
    (VP (VBP:[924..930] report)
      (SBAR (IN:[931..935] that)
        (S
          (NP-SBJ-1
            (NP (NN:[936..945] formation))
            (PP (IN:[946..948] of)
              (NP (DT:[949..954] these) (JJ:[955..965] oxygenated)
                 (NN:[966..978] arachidonate) (NNS:[979..990] metabolites))))
          (VP (VBZ:[991..993] is)
            (VP (VBN:[994..1004] stimulated)
              (NP-1 (-NONE-:[1004..1004] *))
              (PP (IN:[1006..1008] by)
                (NP-LGS
                  (NP
                    (NP (NN:[1009..1017] arginine) (NN:[1018..1029] vasopressin))
                    (NP (-LRB-:[1030..1031] -LRB-) (NN:[1031..1034] AVP)
                        (-RRB-:[1034..1035] -RRB-)))
                  (CC:[1036..1039] and)
                  (NP
                    (NP (NN:[1040..1046] salmon) (NN:[1047..1057] calcitonin))
                    (NP (-LRB-:[1058..1059] -LRB-) (NN:[1059..1062] SCT)
                        (-RRB-:[1062..1063] -RRB-))))))))))
    (.:[1063..1064] .)))

;sentence 7 Span:1065..1237
;In mTALH cells  obtained from rabbits made hypertensive by aortic
;constriction there was a  selective increase in P1 and P2 formation compared
;to other renomedullary cells.
;[1179..1181]:substance:"P1"
;[1186..1188]:substance:"P2"
(SENT
  (S
    (PP-LOC (IN:[1065..1067] In)
      (NP
        (NP (NN:[1068..1073] mTALH) (NNS:[1074..1079] cells))
        (VP (VBN:[1081..1089] obtained)
          (NP (-NONE-:[1089..1089] *))
          (PP (IN:[1090..1094] from)
            (NP
              (NP (NNS:[1095..1102] rabbits))
              (VP (VBN:[1103..1107] made)
                (S
                  (NP-SBJ (-NONE-:[1107..1107] *))
                  (ADJP-PRD (JJ:[1108..1120] hypertensive)))
                (PP (IN:[1121..1123] by)
                  (NP-LGS (JJ:[1124..1130] aortic)
                          (NN:[1131..1143] constriction)))))))))
    (NP-SBJ (EX:[1144..1149] there))
    (VP (VBD:[1150..1153] was)
      (NP-PRD
        (NP (DT:[1154..1155] a) (JJ:[1157..1166] selective)
            (NN:[1167..1175] increase))
        (PP (IN:[1176..1178] in)
          (NP
            (NP (NN:[1179..1181] P1)
              (NML-2 (-NONE-:[1181..1181] *P*)))
            (CC:[1182..1185] and)
            (NP (NN:[1186..1188] P2)
              (NML-2 (NN:[1189..1198] formation))))))
      (S-ADV
        (NP-SBJ-1 (-NONE-:[1198..1198] *))
        (VP (VBN:[1199..1207] compared)
          (NP-1 (-NONE-:[1207..1207] *))
          (PP-CLR (TO:[1208..1210] to)
            (NP (JJ:[1211..1216] other) (JJ:[1217..1230] renomedullary)
                (NNS:[1231..1236] cells))))))
    (.:[1236..1237] .)))

;section 8 Span:1241..1271
;Publication Types:      Review
(SEC
  (FRAG (NNP:[1241..1252] Publication) (NNP:[1253..1258] Types)
        (NNP:[1258..1259] :) (NNP:[1265..1271] Review)))

;section 9 Span:1275..1319
;PMID: 3021941 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1275..1279] PMID) (::[1279..1280] :) (CD:[1281..1288] 3021941)
        (NN:[1289..1290] -LSB-) (NNP:[1290..1296] PubMed) (::[1297..1298] -)
        (NN:[1299..1306] indexed) (IN:[1307..1310] for)
        (NNP:[1311..1319] MEDLINE-RSB-)))
